Factors affecting long-term changes of meibomian gland in MGD patients
- PMID: 37650897
- DOI: 10.1007/s00417-023-06210-1
Factors affecting long-term changes of meibomian gland in MGD patients
Abstract
Purpose: To explore the long-term course of patients with meibomian gland dysfunction (MGD), and to analyse potential factors affecting the recovery of meibomian gland (MG) dropout.
Methods: Seventy-nine MGD patients (79 eyes) aged 36.03±15.78 years old who underwent more than one year of follow-up were enrolled in this retrospective study. Corneal fluorescein staining (CFS), tear meniscus height (TMH), noninvasive breakup time (NIBUT), and noncontact meibography at baseline and last visit were collected and analysed. Then an automatic MG analyzer was used to measure the morphological and functional parameters of MGs, including their area ratio (AR), tortuosity index (TI), and signal index (SI). The patients whose AR increased by more than 5% were defined as MG improvement, and AR decreased by more than 5% was MG worsening.
Results: A total of 79 patients (79 eyes) were assessed with at least 1-year of follow-up. More than 1/3 of MGD patients (27 eyes, 34.2%) underwent MG improvement, and 30.4% of MGs became worsened. Age (P=0.002), gender (P<0.001), IPL treatment (P=0.013), the change of CFS (P=0.0015), and the recovery of SI (P=0.035) showed significant differences among different recovery groups. Age(P<0.001), female sex (P=0.003), ΔCFS (P<0.001), AR at baseline (P<0.001) were negative correlation with AR recovery, and the change of SI (P=0.003) and IPL treatment (P=0.003) had a positive correlation with it. Among them, age (P=0.038), the change of CFS (P=0.004), and AR at baseline (P=0.007) were confirmed as negatively correlated factors predicting the long-term change of the MG.
Conclusion: Although the MGD treatment has continued for more than 1 year, only 34.2% of MGD patients were observed to undergo MG improvement. Younger patients and patients with better CFS recovery seem to have more opportunities to improve their MGs.
Keywords: Factors; Long-term change; Meibomian gland; Meibomian gland dysfunction.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Intense pulse light therapy treatment for refractory dry eye disease due to meibomian gland dysfunction.Int Ophthalmol. 2020 May;40(5):1135-1141. doi: 10.1007/s10792-019-01278-3. Epub 2020 Jan 8. Int Ophthalmol. 2020. PMID: 31916061
-
Comparative Evaluation in Intense Pulsed Light Therapy Combined with or without Meibomian Gland Expression for the Treatment of Meibomian Gland Dysfunction.Curr Eye Res. 2021 Aug;46(8):1125-1131. doi: 10.1080/02713683.2020.1867750. Epub 2021 Jan 18. Curr Eye Res. 2021. PMID: 33342317 Clinical Trial.
-
Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction.Cochrane Database Syst Rev. 2020 Mar 18;3(3):CD013559. doi: 10.1002/14651858.CD013559. Cochrane Database Syst Rev. 2020. PMID: 32182637 Free PMC article.
-
Categorization of Meibomian Gland Dysfunction Using Lipid Layer Thickness and Meibomian Gland Dropout in Dry Eye Patients: A Retrospective Study.Korean J Ophthalmol. 2024 Feb;38(1):64-70. doi: 10.3341/kjo.2023.0126. Epub 2023 Dec 27. Korean J Ophthalmol. 2024. PMID: 38148689 Free PMC article.
-
Prospective evaluation of a new intense pulsed light, thermaeye plus, in the treatment of dry eye disease due to meibomian gland dysfunction.J Optom. 2021 Apr-Jun;14(2):103-113. doi: 10.1016/j.optom.2020.08.009. Epub 2020 Oct 26. J Optom. 2021. PMID: 33121905 Free PMC article. Review.
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials